WO2015066452A3 - Methods of treating pediatric cancers - Google Patents
Methods of treating pediatric cancers Download PDFInfo
- Publication number
- WO2015066452A3 WO2015066452A3 PCT/US2014/063384 US2014063384W WO2015066452A3 WO 2015066452 A3 WO2015066452 A3 WO 2015066452A3 US 2014063384 W US2014063384 W US 2014063384W WO 2015066452 A3 WO2015066452 A3 WO 2015066452A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- pediatric cancers
- treating pediatric
- treating
- cancers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
Methods and compositions for treating pediatric cancers are disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361898835P | 2013-11-01 | 2013-11-01 | |
US61/898,835 | 2013-11-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015066452A2 WO2015066452A2 (en) | 2015-05-07 |
WO2015066452A3 true WO2015066452A3 (en) | 2015-06-04 |
Family
ID=53005386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/063384 WO2015066452A2 (en) | 2013-11-01 | 2014-10-31 | Methods of treating pediatric cancers |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015066452A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
DK3176170T3 (en) | 2012-06-13 | 2019-01-28 | Incyte Holdings Corp | SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
ES2893725T3 (en) | 2013-04-19 | 2022-02-09 | Incyte Holdings Corp | Bicyclic heterocyclics as FGFR inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
CN107438607B (en) | 2015-02-20 | 2021-02-05 | 因赛特公司 | Bicyclic heterocycles as FGFR inhibitors |
MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
AU2017238390A1 (en) * | 2016-03-23 | 2018-09-27 | Dana-Farber Cancer Institute, Inc. | Compositions, assays, and methods for targeting HDM2 and HDMX to reverse the inhibition of p53 in pediatric cancers |
CN106011051B (en) * | 2016-07-01 | 2020-01-21 | 中山大学 | Application of Bend5 protein in improving differentiation of embryonic stem cells into primitive germ-like cells by induction |
WO2018081204A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | DEUTERATED N-(5-((4-ETHYLPIPERAZIN-1-YL)METHYL) PYRIDIN-2-YL)-5-FLUORO-4-(4-FLUORO-1-ISOPROPYL-2-METHYL-1H-BENZO[d]IMIDAZOL-6-YL)PYRIMIDIN-2-AMINE |
ES2928773T3 (en) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Protein kinase inhibitors to promote liver regeneration or reduce or prevent hepatocyte death |
CN108794452B (en) | 2017-05-05 | 2021-05-28 | 上海时莱生物技术有限公司 | Compound with kinase inhibition activity, preparation method and application thereof |
AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
RU2020133814A (en) | 2018-03-19 | 2022-04-19 | Такеда Фармасьютикал Компани Лимитед | METHODS FOR TREATMENT OF CANCER IN CHILDHOOD PATIENTS |
MA52493A (en) | 2018-05-04 | 2021-03-10 | Incyte Corp | FGFR INHIBITOR SALTS |
BR112020022392A2 (en) | 2018-05-04 | 2021-02-02 | Incyte Corporation | solid forms of a fgfr inhibitor and processes for preparing them |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
JP2020162420A (en) | 2019-03-28 | 2020-10-08 | シスメックス株式会社 | Method for determining sensitivity of cyclin-dependent kinase 4/6 inhibitor, reagent kit, device and computer program |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CR20220169A (en) | 2019-10-14 | 2022-10-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JP2023505258A (en) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Tricyclic heterocycles as FGFR inhibitors |
WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
US20230340485A1 (en) * | 2020-06-16 | 2023-10-26 | Alnylam Pharmaceuticals, Inc. | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012068030A1 (en) * | 2010-11-15 | 2012-05-24 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins |
WO2012108782A1 (en) * | 2011-02-07 | 2012-08-16 | Общество С Ограниченной Ответственностью "Онкомакс" | Antibody that stops or slows tumour growth (variants) |
-
2014
- 2014-10-31 WO PCT/US2014/063384 patent/WO2015066452A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012068030A1 (en) * | 2010-11-15 | 2012-05-24 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins |
WO2012108782A1 (en) * | 2011-02-07 | 2012-08-16 | Общество С Ограниченной Ответственностью "Онкомакс" | Antibody that stops or slows tumour growth (variants) |
US20140105821A1 (en) * | 2011-02-07 | 2014-04-17 | llya Valer'evich Tymofeev | Antibody that stops or slows tumour growth (variants) |
Non-Patent Citations (9)
Title |
---|
ALI ET AL.: "Abstract A28: Clinical next-generation sequencing (NGS) reveals genomic alterations (GAs) to guide targeted therapy in advanced neuroblastoma patients", CANCER RES, vol. 74, 15 October 2014 (2014-10-15) * |
BRESLER ET AL.: "Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma", SCI TRANSL MED, vol. 3, no. 108, 9 November 2011 (2011-11-09), pages 108RA114 1 - 10 * |
DIECI ET AL.: "Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.", CANCER DISCOV, vol. 3, no. 3, March 2013 (2013-03-01), pages 264 - 279 * |
HOWMAN-GILES ET AL.: "Neuroblastoma and other neuroendocrine tumors.", SEMIN NUCL MED., vol. 37, no. 4, July 2007 (2007-07-01), pages 286 - 302 * |
JONES ET AL.: "Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma", NAT, vol. 45, no. 8, 2013, pages 927 - 932 * |
LEW W ET AL.: "The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations", SCI SIGNAL, vol. 2, no. 58, 17 February 2009 (2009-02-17), pages RA6 1 - 11 * |
MYUNG ET AL.: "Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors", TRANSL ONCOL, vol. 5, no. 6, December 2012 (2012-12-01), pages 430 - 436 * |
RAND ET AL.: "Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas", PROC NAT ACAD SCI, vol. 102, no. 40, 4 October 2005 (2005-10-04), pages 14344 - 14349 * |
SAMPSON ET AL.: "A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma", FRONT ONCOL, vol. 3, no. 132, 31 May 2013 (2013-05-31), pages 1 - 12 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015066452A2 (en) | 2015-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015066452A3 (en) | Methods of treating pediatric cancers | |
IL273090B (en) | Methods and compositions for the treatment of cancer | |
EP3166640A4 (en) | Combination therapy compositions and methods for treating cancers | |
EP3060207A4 (en) | Methods and compositions for treating cancer | |
EP3038610A4 (en) | Compositions and methods for the treatment of presbyopia | |
EP3027192A4 (en) | Methods for the treatment of solid tumors | |
EP3024497A4 (en) | Methods and compositions for treating brain diseases | |
EP3082819A4 (en) | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith | |
AU2017246547A1 (en) | Methods of treating pediatric cancers | |
HK1217896A1 (en) | Compositions and methods for the treatment of pervasive development disorders | |
EP3004396A4 (en) | Methods and compositions for the treatment of cancer | |
EP3322439A4 (en) | Compositions and methods for treating peritoneal cancers | |
EP3347025A4 (en) | Methods and compositions for cancer treatment | |
EP2996721A4 (en) | Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer | |
EP3052102A4 (en) | Compositions and methods for treating cancers | |
EP3004395A4 (en) | Compositions and methods for treating cancer | |
EP3065829A4 (en) | Compositions and methods for treating melanoma | |
EP3154544A4 (en) | Compositions and methods for treating cancers | |
EP3429613A4 (en) | Compositions and methods for treating cancers | |
HK1220374A1 (en) | Compositions and methods for the treatment of carboxyhemoglobinemia | |
EP3185910A4 (en) | Methods and compositions for the treatment of cancer | |
EP3154952A4 (en) | Methods and compositions for treatment of her-positive cancers | |
EP3082427A4 (en) | Compositions and methods for treatment of glaucoma | |
EP3089745A4 (en) | Compounds, compositions, and methods for the treatment of cancers | |
EP2994147A4 (en) | Compositions and methods for the treatment of tinnitus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14858779 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14858779 Country of ref document: EP Kind code of ref document: A2 |